Frank S. Walsh
Founder at Ossianix, Inc.
Network origin in Frank S. Walsh first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Ossianix, Inc.
 Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA.
5
| Holding Company | Pharmaceuticals: Generic | 5 |
Glaxo SmithKline Consumer Healthcare Ltd.
 Glaxo SmithKline Consumer Healthcare Ltd. Medical DistributorsDistribution Services GlaxoSmithKline Consumer Healthcare manufactures and supplies over the counter drugs. It focuses on oral healthcare, over the counter medicines and nutritional healthcare products. Its brands and products include oral care (Aquafresh) to dermatology (Zovirax), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums) and smoking-cessation products (Nicoderm). The company is headquartered in Brentford, UK
2
| Subsidiary | Medical Distributors | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Frank S. Walsh via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Pharmaceuticals: Major | Chairman | |
Renovis, Inc.
 Renovis, Inc. Pharmaceuticals: MajorHealth Technology Renovis, Inc. develops pharmaceutical products. The company discovers, develops, and commercializes novel therapeutics for neurological and inflammatory diseases. It is headquartered in San Francisco, CA | Pharmaceuticals: Major | Founder | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Comptroller/Controller/Auditor | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
| TIGENIX NV | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| MOLMED S.P.A. | Pharmaceuticals: Major | Chairman | |
| GSK PLC | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
Aventis Pharma SARL
 Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Founded in 1982, Aventis Pharma SARL is a French pharmaceutical company that manufactures pharmaceuticals. Part of Sanofi, the company is based in Antony, France. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GlaxoSmithKline Chongqing Co. Ltd.
 GlaxoSmithKline Chongqing Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurora Optoelectronics Co., Ltd., GlaxoSmithKline Chongqing Co. Ltd. is a pharmaceutical company based in Chongqing, CN. GlaxoSmithKline Chongqing Co. was acquired by Aurora Optoelectronics Co., Ltd. from GSK Plc on December 31, 2004 for $12.81 million. The Chinese company manufactures pharmaceutical products. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Hofstra University | College/University | Undergraduate Degree | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Founder Director/Board Member | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| Aventis Pharma AG | Corporate Officer/Principal | ||
Sanofi Pasteur
 Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| European Molecular Biology Organization | Corporate Officer/Principal | ||
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Biotechnology | Founder | |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
EryDel SpA
 EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Chairman | |
| The European Association for Bioindustries | Chairman | ||
| IMMUNOVIA AB | Pharmaceuticals: Major | Chairman | |
AiCuris GmbH & Co. KG
 AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| Università degli Studi di Modena e Reggio Emilia | College/University | Doctorate Degree | |
| Nancy-Université | College/University | Doctorate Degree | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder | |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Aventis Pharma Ltd.
 Aventis Pharma Ltd. Medical DistributorsDistribution Services Part of Sanofi, Aventis Pharma Ltd. is a British company that engages in the wholesale of pharmaceutical goods. The company is based in Reading, UK. Aventis Pharma was founded in 1980. | Medical Distributors | Corporate Officer/Principal | |
Janssen Vaccines AG
 Janssen Vaccines AG Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Janssen Vaccines AG is a Swiss company that manufactures and distributes vaccines and immunotherapeutic products. The company is based in Bern, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Biotech Research & Innovation Centre | Chairman | ||
InnovationsFonden
 InnovationsFonden Investment ManagersFinance InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark. | Investment Managers | Chief Executive Officer | |
Edvince AB
 Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden. | Biotechnology | Chairman | |
| INVENTIVA | Biotechnology | Chief Tech/Sci/R&D Officer | |
| International Rare Diseases Research Consortium | Corporate Officer/Principal | ||
Nosopharm SAS
 Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Pharmaceuticals: Major | Director/Board Member | |
| MONSENSO A/S | Internet Software/Services | Director/Board Member | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Chairman | |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chairman | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Gotham Therapeutics Corp.
 Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Director/Board Member |
Statistics
International
| United States | 10 |
| France | 8 |
| Netherlands | 7 |
| Denmark | 7 |
| Germany | 5 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 6 |
| Finance | 4 |
| Commercial Services | 3 |
| Process Industries | 2 |
Operational
| Director/Board Member | 85 |
| Corporate Officer/Principal | 48 |
| Chairman | 26 |
| Founder | 22 |
| Independent Dir/Board Member | 17 |
Most connected contacts
| Insiders | |
|---|---|
| Corey Goodman | 35 |
| Peter Andersen | 26 |
| Michael Owen | 20 |
| Sander J. van Deventer | 17 |
| Jean Franchi | 17 |
| Marco Boorsma | 15 |
| Alexander Vos | 15 |
| Marie Paule Richard | 15 |
| Carlo Incerti | 14 |
| Stephen Moon | 10 |
| Thomas Rasmussen | 7 |
| J. Lynn Rutkowski | 4 |
| Steve Moore | 4 |
| Anthony Newcombe | 1 |
| Pavlina Konstantinova | 1 |
- Stock Market
- Insiders
- Frank S. Walsh
- Company connections
